COVAXX Partners With Aurobindo Pharma To Develop COVID-19 Vaccine In India

COVAXX has partnered with Aurobindo Pharma for the production and distribution of UB-612 COVID-19 vaccine in India and the UNICEF.

COVAXX is a US based company that is currently developing UB-612, a multitope peptide-based vaccine against COVID-19 has announced an exclusive agreement with Aurobindo Pharma in order to expand its global development and commercialization of UB-612 to India and the United Nations Children's Fund (UNICEF) agency.

Currently, COVAXX is conducting a Phase 1 clinical trial for the candidate vaccine.

COVID-19: Diet Plan and Lifestyle Modifications for the Unlock Phase
Healthy eating habits and adherence to physical activity are required during COVID-19 lockdown. WHO has prepared a set of general tips that you could follow during the lockdown to stay fit and healthy.

‘COVAXX has partnered with Aurobindo Pharma for the production and distribution of UB-612 COVID-19 vaccine in India and the UNICEF.’
Read More..

Normally all the vaccines are produced by using live or attenuated microorganisms or parts of them. The peptide-based vaccines are synthetic vaccines that mimic the naturally occurring proteins from the infectious pathogens. COVAXX vaccine is fully synthetic and shows no biohazard risk as seen in pre-clinical studies.

Co-founder and CEO of COVAXX, Mei Mei Hu said, “COVAXX is committed to providing an equitable distribution of UB-612 vaccine by prioritizing markets where the unmet need is greatest. During this global health crisis response, we must establish partners with the strongest capabilities, like Aurobindo, to expand the manufacturing and delivery of our vaccine. As one of the leading industry players with a strong track record of execution and investment in vaccines, Aurobindo Pharma is the ideal partner to advance UB-612 in India and other emerging nations and to support our mission of democratizing health worldwide.”

According to the signed agreement, Aurobindo Pharma has the exclusive rights to develop, manufacture and sell Covaxx's UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in other select emerging and developing markets.

Zydus Cadila COVID-19 Vaccine Found Safe in Clinical Trials
In the phase I and II clinical trials, Zydus Cadila announced that its plasmid DNA vaccine to prevent COVID-19 - ZyCoV-D - was found to be safe, well tolerated and immunogenic.

The finished doses of UB-612 will be manufactured by Aurobindo Pharma at its facility in Hyderabad.

Currently, Aurobindo Pharma has the capacity of manufacturing 220 million (22 crore) doses in multi-dose presentation. It is also building additional facilities to have a total capacity of nearly 480 million (48 crore) doses by June 2021.

Kid's Emotion Inferences from Masked Faces During the COVID-19 Pandemic
Children struggle to recognize the emotions of mask-wearing faces during the covid-19 pandemic, according to a new study.

Commenting on the development, Mr. N. Govindarajan, Managing Director, Aurobindo Pharma Limited, said, “We are proud to join hands with COVAXX for developing the first-ever peptide-based vaccine to combat the COVID-19 pandemic. This vaccine has immense potential in eliminating shedding and hence containing the spread of the pandemic.”

Source-Medindia

New Variants of COVID-19 Reported in Portugal
In Portugal, three new variants of the novel coronavirus were reported, said a top health official. The three COVID-19 variants detected detected are in a process of adaptation of the virus to humans.